Translational Development Acquisition (TDACU) Accumulated Expenses (2023 - 2025)

Translational Development Acquisition has reported Accumulated Expenses for 3 years, with the latest figure at $75000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 60.96% year-over-year to $75000.0; the trailing twelve-month figure through Dec 2025 stood at $75000.0 (down 60.96% YoY), and the FY2025 full-year result was $75000.0, down 60.96% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $75000.0, roughly flat from $75000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $192114.0 in Q4 2024, with the low at $75000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $108840.2 across 3 years, with a median of $75000.0 in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses gained 19.38% — and 2025, when it tumbled 60.96%.
• Translational Development Acquisition's Accumulated Expenses stood at $160927.0 in 2023, then grew by 19.38% to $192114.0 in 2024, then plunged by 60.96% to $75000.0 in 2025.
• The last three Accumulated Expenses figures came in at $75000.0 (Q4 2025), $75000.0 (Q3 2025), and $75000.0 (Q2 2025), per Business Quant data.